SPONSORED CONTENT
As 2026 reaches its midpoint, 340B covered entities (CEs) are operating in an environment defined less by one sweeping policy change and more by the accumulation of operational pressure across the program.
While questions remain around rebate-based models and broader program reform, the immediate reality is already taking shape. Manufacturer requirements, third-party platform processes, claims-level data requests, and increasing documentation expectations are influencing how 340B is managed day to day, often without a unified framework.
For many organizations, the result is a growing gap between how the program is intended to function, the reality of how it functions today, and misrepresentation of the program to the public.
The Model May Be Uncertain, but the Pressure Is Not
The future of a formal 340B rebate model remains uncertain. After legal and regulatory activity earlier this year, HRSA is continuing to review stakeholder feedback and determine next steps. But even without a finalized rebate model, elements of that structure are already appearing in operational workflows.
CEs are navigating:
- Manufacturer-specific submission requirements through third-party platforms
- Claims-level data requests across contract pharmacy, in-house pharmacy, and medical benefit utilization
- Increased scrutiny around eligibility validation and documentation
- Expanding reconciliation efforts across pharmacy, compliance, and financial systems
These developments are not part of one coordinated change, but they are shaping behavior in ways that resemble a more complex, multi-step reimbursement environment.
Organizations are adapting in real time, often by layering new processes onto systems and workflows that were not designed for this level of variation.
Operational Complexity Is Increasing Across the Board
The operational footprint required to manage 340B has expanded. What was once a more linear process—dispense, document, purchase—now involves multiple validation points, external platforms, manufacturer-specific rules, and ongoing reconciliation activities.
This complexity shows up in several areas:
- Managing variations in manufacturer requirements
- Tracking submissions across different systems and timelines
- Aligning pharmacy data with financial reporting
- Maintaining audit-ready documentation across workflows
- Monitoring how contract pharmacy restrictions and “universal” claim level data submission
- State-to-State variation in laws and policies
For many teams, these responsibilities are being absorbed into existing structures rather than supported by fully integrated processes. That creates additional pressure on pharmacy, compliance, finance, and IT teams that already manage significant day-to-day demands.
Financial Visibility Is Becoming Harder to Maintain
As workflows become more fragmented, maintaining clear financial visibility becomes more difficult.
CEs may face challenges in:
- Tracking expected versus realized savings
- Identifying delays or discrepancies in reimbursement or replenishment activity
- Connecting operational data to financial outcomes and increased up-front costs
- Forecasting the potential impact of changing manufacturer requirements
- Managing multiple payment streams
These issues are not limited to pharmacy operations. They increasingly affect finance teams responsible for forecasting, reporting, and margin management. In an environment where timing and accuracy matter, even small gaps in visibility can have broader implications.
For CEs, the question is not only whether 340B savings are being captured. It is whether teams can clearly see where savings are expected, where they may be delayed, and where process gaps may create risk.
Fragmentation Is Emerging as a Central Risk
One of the defining characteristics of the current 340B environment is fragmentation. Data, workflows, and accountability are often distributed across:
- Pharmacy teams
- Finance departments
- Compliance functions
- External administrators and platforms
- Manufacturer-specific submission processes
As requirements grow, that fragmentation becomes more difficult to manage. Without alignment across these areas, organizations may experience delayed identification of discrepancies, increased effort to support audits, and reduced confidence in
reported outcomes.
What was once manageable complexity is becoming harder to sustain.
Where CEs Are Focusing Now
In response, many organizations are shifting their focus toward strengthening operational fundamentals.
Key areas of focus include:
Improving cross-functional visibility
Bringing pharmacy, financial, and compliance data into closer alignment to support more accurate tracking, reporting, and decision-making.
Standardizing processes
Refining how submissions are automated, and how exceptions are managed. Focus on submitting only data that is required for each respective manufacturer program.
Minimizing manual dependencies
Identifying where manual tracking, spreadsheets, or disconnected reconciliation efforts create risk as volume and complexity increase.
Enhancing audit readiness
Ensuring documentation is consistent, accessible, and aligned across all aspects of 340B and Revenue operations.
Preparing for multiple outcomes
Building processes that can support today’s requirements while remaining flexible enough to adapt when rebate models, manufacturer policies, or state-level actions further change the operating environment.
These efforts are not tied to a single policy outcome. They reflect a broader need to manage rising complexity more effectively.
A Program Increasingly Defined by Execution
As the 340B program continues to evolve, the defining challenge is becoming less about participation and more about execution.
CEs are being asked to manage a program that is more dynamic, more fragmented, and more closely scrutinized than in previous years. This shift is not driven by one change alone, but by the accumulation of new requirements, data expectations, processes, and oversight mechanisms across the program.
Looking Ahead
There is still uncertainty around how the 340B program may evolve at the policy level. What is clearer is the operational direction: increased complexity, greater expectations for transparency, and a continued need for alignment across systems and teams.
CEs are also watching adjacent pricing reforms such as GLOBE, GUARD, and GENEROUS—not because they are 340B policy changes themselves, but because they point to a broader reimbursement environment that is becoming more benchmark-driven, rebate-oriented, and administratively complex.
For CEs, the most immediate priority is not predicting every future policy decision. It is strengthening the processes, visibility, and controls needed to manage what is already in motion.
Because in the current environment, the challenge is not waiting for change — It is keeping up with it.
Wyley McCoy is Senior Vice President, Medication and Supplies at
The Craneware Group. He can be reached at wmccoy@craneware.com.
